Advertisement

Clinical Drug Investigation

, Volume 38, Issue 9, pp 829–835 | Cite as

Coagulant Effect and Tolerability of Yeast-Produced Recombinant Batroxobin in Healthy Adult Subjects

  • Seuk Keun Choi
  • Chan Wha Kim
  • Jong-Tak Kim
  • Young Seomun
  • Min Soo Park
  • Choon Ok KimEmail author
Original Research Article

Abstract

Background and Objective

Batroxobin, a snake venom thrombin-like enzyme, converts fibrinogen into fibrin by cleaving fibrinopeptide A. It is used for hemostasis; however, the supply of native batroxobin is limited. Therefore, we developed a recombinant batroxobin (r-batroxobin) from Pichia pastoris and evaluated its pharmacodynamics and safety in humans.

Methods

A randomized, double-blind, placebo-controlled, single ascending-dose study was performed. Eight healthy subjects were enrolled in each r-batroxobin dose group (2.5, 5.0, or 10.0 BU/2.0 mL administered intravenously), and randomized to receive r-batroxobin (n = 6) or matching placebo (n = 2). Safety was evaluated during the study, and pharmacodynamics was assessed using prothrombin time (PT), activated partial thromboplastin time (aPTT), thrombin time (TT), and fibrinogen level.

Results

All subjects in each cohort completed the study. No significant changes in PT or aPTT occurred after intravenous r-batroxobin administration. Compared with the placebo group, the fibrinogen level in all r-batroxobin dose groups decreased significantly to 8.68–33.57% from the baseline within 12 h (p ≤ 0.05). The TT in the 5.0 and 10.0 BU/2.0 mL groups significantly increased to 7.53–18.48% from baseline within 12 h compared with that of the placebo group (p ≤ 0.05), whereas that of the 2.5 BU/2.0 mL group exhibited non-significant changes compared with the placebo group. No serious adverse events occurred.

Conclusions

A single intravenous injection of r-batroxobin within a dose range of 2.5–10.0 BU/2.0 mL was well tolerated and resulted in a significant decrease in fibrinogen and prolongation of TT.

Registration

This study is registered at the Clinical Research Information Service (CRIS, http://cris.nih.go.kr), number KCT0002518.

Notes

Acknowledgements

We would like to thank the staff at Severance Hospital Clinical Trials Center for their generous cooperation. This randomized clinical trial is registered at the Clinical Research Information Service (CRIS, http://cris.nih.go.kr), number KCT0002518.

Author Contributions

Conceptualization: MSP and COK. Conduct of clinical study: COK, MSP, JTK, and YS. Data curation: SKC. Formal analysis: SKC, CWK, and COK; Writing-original manuscript: SKC and COK.

Compliance with Ethical Standards

Funding

This study was funded by NC bit Inc., Seongnam, Korea.

Conflict of interest

Jong-Tak Kim and Young Seomun are full-time employees of NC bit Inc, but they did not play a major role in the study design or data analysis. The other authors report no conflicts of interest related to this work.

Ethical approval

Institutional Review Board (IRB) of Severance Hospital, Yonsei University College of Medicine (Seoul, Korea) approved the study protocol before the study was conducted (IRB number: 4-2014-0661). All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Kauvar DS, Wade CE. The epidemiology and modern management of traumatic hemorrhage: US and international perspectives. Crit Care. 2005;9(Suppl 5):S1–9.CrossRefGoogle Scholar
  2. 2.
    Rossaint R, Bouillon B, Cerny V, Coats TJ, Duranteau J, Fernandez-Mondejar E, et al. The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition. Crit Care. 2016;20:100.Google Scholar
  3. 3.
    Davenport R, Khan S. Management of major trauma haemorrhage: treatment priorities and controversies. Br J Haematol. 2011;155(5):537–48.CrossRefGoogle Scholar
  4. 4.
    Douketis JD, Berger PB, Dunn AS, Jaffer AK, Spyropoulos AC, Becker RC, et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):299S–339S.Google Scholar
  5. 5.
    Seghatchian J, Samama MM. Massive transfusion: an overview of the main characteristics and potential risks associated with substances used for correction of a coagulopathy. Transf Apher Sci. 2012;47(2):235–43.CrossRefGoogle Scholar
  6. 6.
    Sihler KC, Napolitano LM. Complications of massive transfusion. Chest. 2010;137(1):209–20.CrossRefGoogle Scholar
  7. 7.
    Schulman S. Pharmacologic tools to reduce bleeding in surgery. Hematol Am Soc Hematol Educ Program. 2012;2012:517–21.Google Scholar
  8. 8.
    Kumar VA, Wickremasinghe NC, Shi S, Hartgerink JD. Nanofibrous snake venom hemostat. ACS Biomater Sci Eng. 2015;1(12):1300–5.CrossRefGoogle Scholar
  9. 9.
    Seon GM, Lee MH, Kwon BJ, Kim MS, Koo MA, Kim D, et al. Functional improvement of hemostatic dressing by addition of recombinant batroxobin. Acta Biomater. 2017;48:175–85.CrossRefGoogle Scholar
  10. 10.
    Hu H, Chen L, Frary CE, Chang C, Hui H, Zhang H, et al. The beneficial effect of Batroxobin on blood loss reduction in spinal fusion surgery: a prospective, randomized, double-blind, placebo-controlled study. Arch Orthop Trauma Surg. 2015;135(4):491–7.CrossRefGoogle Scholar
  11. 11.
    Aronson DL. Comparison of the actions of thrombin and the thrombin-like venom enzymes ancrod and batroxobin. Thromb Haemost. 1976;36(1):9–13.CrossRefGoogle Scholar
  12. 12.
    You W, Choi W, Koh Y, Shin H, Jang Y, Chung K. Functional characterization of recombinant batroxobin, a snake venom thrombin-like enzyme, expressed from Pichia pastoris. FEBS Lett. 2004;571(1–3):67–73.CrossRefGoogle Scholar
  13. 13.
    Lochnit G, Geyer R. Carbohydrate structure analysis of batroxobin, a thrombin-like serine protease from Bothrops moojeni venom. Eur J Biochem. 1995;228(3):805–16.CrossRefGoogle Scholar
  14. 14.
    Jayandharan G, Nair S, Poonnoose P, Thomas R, John J, Keshav S, et al. Polymorphism in factor VII gene modifies phenotype of severe haemophilia. Haemophilia. 2009;15(6):1228–36.CrossRefGoogle Scholar
  15. 15.
    Key NS, Makris M, Lillicrap D. Practical hemostasis and thrombosis. 3rd ed. Chichester, West Sussex: Wiley; 2017.Google Scholar
  16. 16.
    Hughes-Jones NC, Wickramasinghe SN, Hatton C. Lecture notes haematology. Chichester: Wiley; 2008.Google Scholar
  17. 17.
    Tanaka KA, Key NS, Levy JH. Blood coagulation: hemostasis and thrombin regulation. Anesth Analg. 2009;108(5):1433–46.CrossRefGoogle Scholar
  18. 18.
    Xu C, Wu A, Yue Y. Which is more effective in adolescent idiopathic scoliosis surgery: batroxobin, tranexamic acid or a combination? Arch Orthop Trauma Surg. 2012;132(1):25–31.CrossRefGoogle Scholar
  19. 19.
    Liu KA, Dipietro Mager NA. Women’s involvement in clinical trials: historical perspective and future implications. Pharm Pract (Granada). 2016;14(1):1–9.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of BiotechnologyKorea UniversitySeoulSouth Korea
  2. 2.R&D Center, NC bit Inc.SeongnamSouth Korea
  3. 3.Department of Clinical Pharmacology and Clinical Trials Center, Severance HospitalYonsei University Health SystemSeoulSouth Korea
  4. 4.Department of PediatricsYonsei University College of MedicineSeoulSouth Korea

Personalised recommendations